Leukemia Research
Volume 27, Issue 9 , Pages 795-802 , September 2003

Dendritic cell vaccination for patients with chronic myelogenous leukemia

  • Tsuyoshi Takahashi

      Affiliations

    • Department of Hematology and Oncology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
    • Department of Transfusion Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
    • ,
  • Yuji Tanaka

      Affiliations

    • Division of Hematology, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, Japan
    • ,
  • Mie Nieda

      Affiliations

    • Department of Research, The Japanese Red Central Blood Center, 4-1-31 Hiroo, Shibuya-ku, Tokyo, Japan
    • ,
  • Takeshi Azuma

      Affiliations

    • Department of Urology, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
    • ,
  • Shigeru Chiba

      Affiliations

    • Department of Hematology and Oncology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
    • ,
  • Takeo Juji

      Affiliations

    • Department of Research, The Japanese Red Central Blood Center, 4-1-31 Hiroo, Shibuya-ku, Tokyo, Japan
    • ,
  • Yoichi Shibata

      Affiliations

    • Department of Transfusion Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
    • ,
  • Hisamaru Hirai

      Affiliations

    • Department of Hematology and Oncology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-3-5804-6690; fax: +81-3-5689-7286.

Received 10 October 2002 ,Accepted 21 December 2002.

References 

  1. Hart DNJ. Dendritic cells: unique leukocyte populations, which control the primary immune response. Blood. 1997;90:3245–3287
  2. Banchereau J, Steinmen RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252
  3. Cella M, Sallusto F, Lanzavecchia A. Origin. Cur. Opin. Immunol. 1997;9:10–16
  4. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 1996;183:283–287
  5. Porgador A, Snyder D, Gilboa E. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 1996;156:2918–2926
  6. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, et al.  Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 1996;183:87–97
  7. Hsu F, Benike C, Fagnoni F, Liles TM, Czerwiniski D, Taidi B, et al.  Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 1996;2:52–58
  8. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A*0201-specific peptides from prostate-specific membrane antigen. Prostate. 1996;29:371–380
  9. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al.  Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 1998;4:328–332
  10. Wen YJ, Ling M, Bailey-Wood R, Lim SH. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin. Cancer Res. 1998;4:957–962
  11. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. Mechanisms of disease: the biology of chronic myeloid leukemia. N. Engl. J. Med. 1999;341:164–172
  12. Ten Bosch GJA, Toornvliet AC, Friede T, Melief CJM, Leeksma OC. Recognition of peptides corresponding to the joining region of p210bcr-abl protein by human T cells. Leukemia. 1995;9:1344–1348
  13. Boccia M, Korontsvit T, Mackinnon Xu Q, Yong Yang S, Sette A, Scheinberg DA. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood. 1996;87:3587–3592
  14. Yotnda P, Huseyin F, Garcia-Pons F, Garcia Z, Gourru G, Vernant JP, et al.  Cytotoxic T-cell response against the chimeric p210bcr-abl protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 1998;101:2290–2296
  15. Nieda M, Nicol A, Kikuchi A, Kashiwase K, Taylor K, Suzuki K, et al.  Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood. 1998;91:977–983
  16. Osman Y, Takahashi M, Zheng Z, Koike T, Toba K, Liu A, et al.  Generation of bcr-abl specific cytotoxic T-lymphocytes by using of dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusion in marrow grafted CML patients. Leukemia. 1999;13:166–174
  17. Choudhury A, Gajewski J, Liang JC, Popat U, Claxton DE, Kliche KO, et al.  Use of leukemic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 1997;89:1133–1142
  18. Muller L, Provenzani C, Faul C, Pawelec G. Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient’s dendritic cells. Br. J. Haematol. 2001;112:740–748
  19. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, et al.  Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000;95:1781–1787
  20. Fujii S, Shimizu K, Fujimoto K, Kiyokawa T, Shimomura T, Kinoshita M, et al.  Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn. J. Cancer Res. 1999;90:1117–1129
  21. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al.  Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 1999;190:1669–1678
  22. Baggers J, Ratzinger G, Young J. Dendritic cells as immunologic adjuvants for the treatment of cancer. J. Clin. Oncol. 2000;18:3879–3882
  23. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection inpatients with metastatic malignancies. Cancer Res. 1999;59:56–58
  24. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al.  Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001;344:1031–1037

PII: S0145-2126(03)00011-0

doi: 10.1016/S0145-2126(03)00011-0

Leukemia Research
Volume 27, Issue 9 , Pages 795-802 , September 2003

Article Tools

* Image Usage & Resolution